# Seres Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:c4177707-1e3b-479b-a921-804ecb824248 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/seres-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 19 | | Claims under review | 1 | | Evidence records | 8 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-15T04:47:02.512036+00:00 | | Last reviewed | 2026-10-15T04:47:02.512036+00:00 | ## Identity - Legal name: Seres Therapeutics, Inc. - Display name: Seres Therapeutics, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-15T04:47:02.512036+00:00 | | Completeness | 0.364 | | Record Quality | 0.854 | | Directors | 9 | | Committees | 0 | | Governance events | 15 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | NOT_REVIEWED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Craig E. Fraser: Director. Status: current. Independent: true. Since: 2023-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:5 - Dennis A. Ausiello, M.D.: Director. Status: current. Independent: true. Since: 2015-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:6 - Eric D. Shaff: Director. Status: current. Independent: false. Since: 2019-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:7 - Hans-Juergen Woerle, M.D., Ph.D.: Director. Status: current. Independent: true. Since: 2025-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:8 - Kurt C. Graves: Director. Status: current. Independent: true. Since: 2015-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:9 - Paul R. Biondi: Director. Status: current. Independent: true. Since: 2020-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:10 - Richard N. Kender: Director. Status: current. Independent: true. Since: 2014-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:11 - Stephen A. Berenson: Director. Status: current. Independent: true. Since: 2019-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:12 - Willard H. Dere, M.D.: Director. Status: current. Independent: true. Since: 2017-01-01. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:13 ## Executive leadership - Kelly Brady, M.S.: Executive Vice President, Chief Operating Officer [COO]. Status: current. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:14 - Marella Thorell: Executive Vice President, Chief Financial Officer [CFO]. Status: current. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:15 - Matthew Henn, Ph.D.: President and Chief Scientific Officer [PRESIDENT]. Status: current. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:16 - Richard N. Kender: Executive Chair and Interim Chief Executive Officer [CEO]. Status: current. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:17 - Teresa L. Young, Ph.D.: Executive Vice President, Chief Commercial and Strategy Officer. Status: current. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:18 - Thomas J. DesRosier: Executive Vice President, Chief Legal Officer [GC]. Status: current. claim_id=alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:19 ## Governance events - EXECUTIVE_APPOINTED: Kelly Brady, M.S. executive of Seres Therapeutics, Inc., effective 2026-03-12. Effective: 2026-03-12. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1a6qlof1coirlz - CFO_CHANGED: Marella Thorell executive of Seres Therapeutics, Inc., effective 2026-03-12. Effective: 2026-03-12. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1mgyp9e1ycwnmq - EXECUTIVE_APPOINTED: Matthew Henn, Ph.D. executive of Seres Therapeutics, Inc., effective 2026-03-12. Effective: 2026-03-12. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1p21dff1e3mswl - CEO_CHANGED: Richard N. Kender executive of Seres Therapeutics, Inc., effective 2026-03-12. Effective: 2026-03-12. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:rvnaa41gqz4t4 - EXECUTIVE_APPOINTED: Teresa L. Young, Ph.D. executive of Seres Therapeutics, Inc., effective 2026-03-12. Effective: 2026-03-12. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1590jh418033du - GC_CHANGED: Thomas J. DesRosier executive of Seres Therapeutics, Inc., effective 2026-03-12. Effective: 2026-03-12. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:14opsrzd5kkwz - DIRECTOR_APPOINTED: Hans-Juergen Woerle, M.D., Ph.D. seat on Seres Therapeutics, Inc., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:9v9y691v59pgd - DIRECTOR_APPOINTED: Craig E. Fraser seat on Seres Therapeutics, Inc., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:6xuqp219562d2 - DIRECTOR_APPOINTED: Paul R. Biondi seat on Seres Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1gblrnfqi6gst - DIRECTOR_APPOINTED: Eric D. Shaff seat on Seres Therapeutics, Inc., effective 2019-01-01. Effective: 2019-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:zpctjx1xu65gl - DIRECTOR_APPOINTED: Stephen A. Berenson seat on Seres Therapeutics, Inc., effective 2019-01-01. Effective: 2019-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:18x7fv71kn1ixp - DIRECTOR_APPOINTED: Willard H. Dere, M.D. seat on Seres Therapeutics, Inc., effective 2017-01-01. Effective: 2017-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1ht7uverhe2cu - DIRECTOR_APPOINTED: Dennis A. Ausiello, M.D. seat on Seres Therapeutics, Inc., effective 2015-01-01. Effective: 2015-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1eqg0h017u7sq8 - DIRECTOR_APPOINTED: Kurt C. Graves seat on Seres Therapeutics, Inc., effective 2015-01-01. Effective: 2015-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:1by1b8t48f2kr - DIRECTOR_APPOINTED: Richard N. Kender seat on Seres Therapeutics, Inc., effective 2014-01-01. Effective: 2014-01-01. Detected: 2026-10-15T04:47:02.512036+00:00. event_id=alpha:event:transition:171ddsr14srf5j ## Scoped resources - `alpha://company/seres-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record - `alpha://company/seres-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=identity - `alpha://company/seres-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/seres-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=board - `alpha://company/seres-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=committees - `alpha://company/seres-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=leadership - `alpha://company/seres-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=ownership - `alpha://company/seres-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=financials - `alpha://company/seres-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/seres-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=compensation - `alpha://company/seres-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=governance - `alpha://company/seres-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/seres-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=audit - `alpha://company/seres-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=legal - `alpha://company/seres-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=risk - `alpha://company/seres-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=cyber - `alpha://company/seres-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/seres-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=agents - `alpha://company/seres-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/seres-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=events - `alpha://company/seres-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=relationships - `alpha://company/seres-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=assessments - `alpha://company/seres-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - Craig E. Fraser: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:5. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Dennis A. Ausiello, M.D.: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:6. Valid from: 2015-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Eric D. Shaff: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:7. Valid from: 2019-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Hans-Juergen Woerle, M.D., Ph.D.: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:8. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Kurt C. Graves: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:9. Valid from: 2015-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Paul R. Biondi: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:10. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Richard N. Kender: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:11. Valid from: 2014-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Stephen A. Berenson: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:12. Valid from: 2019-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Willard H. Dere, M.D.: Director. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:13. Valid from: 2017-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab. - Kelly Brady, M.S.: Executive Vice President, Chief Operating Officer. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:14. Valid from: 2026-03-12. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e332688a468de6b7b9a6dbfa5cfe3fa888322ea9522eec1a697b0db9000bc36a. - Marella Thorell: Executive Vice President, Chief Financial Officer. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:15. Valid from: 2026-03-12. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ec2d402734f4328166d6e9529009a7f37cd2f38e619da60a7f49cf0074176ab1. - Matthew Henn, Ph.D.: President and Chief Scientific Officer. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:16. Valid from: 2026-03-12. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cc7282df06bf1457e84fba49b1b5006e71fdb6006f0c9fb11fdaa85d5b5b8012. - Richard N. Kender: Executive Chair and Interim Chief Executive Officer. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:17. Valid from: 2026-03-12. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:0048cf182e700feccd7187b3095004167edeb62ce4ff05a1c7b53c2054b75e07. - Teresa L. Young, Ph.D.: Executive Vice President, Chief Commercial and Strategy Officer. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:18. Valid from: 2026-03-12. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:bfa66d750f86e894aecbec32e93f9813b75dae88ea0a24fe8f70a1c566df5c2c. - Thomas J. DesRosier: Executive Vice President, Chief Legal Officer. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:leadership_role:19. Valid from: 2026-03-12. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c6aff36a5b15a84ab617f6187cd3568cf7a89476653d6afb0d27e6bc321860f2. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Seres Therapeutics, Inc.. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:035a016c17341586d227eb4c99dfb63c051e4de55f6b07f743bcb833bc8fe631. ## Entity Status - Public listing published. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:035a016c17341586d227eb4c99dfb63c051e4de55f6b07f743bcb833bc8fe631. ## Published Fact - US. Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:035a016c17341586d227eb4c99dfb63c051e4de55f6b07f743bcb833bc8fe631. ## Security Listing - MCRB (NASDAQ). Claim: alpha:claim:company:c4177707-1e3b-479b-a921-804ecb824248:security_listing:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:035a016c17341586d227eb4c99dfb63c051e4de55f6b07f743bcb833bc8fe631. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:035a016c17341586d227eb4c99dfb63c051e4de55f6b07f743bcb833bc8fe631: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/seres-therapeutics-inc). - alpha:projection-evidence:document:bc98b13b4ca55e668fde1d75628a1e5743476678a358bdfa0cf2faf4f1901aab: [Seres Therapeutics, Inc. DEF 14A 2025-03-13](https://www.sec.gov/Archives/edgar/data/1609809/000095017025038441/mcrb-20250313.htm). - alpha:projection-evidence:document:e332688a468de6b7b9a6dbfa5cfe3fa888322ea9522eec1a697b0db9000bc36a: [MCRB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm). - alpha:projection-evidence:document:ec2d402734f4328166d6e9529009a7f37cd2f38e619da60a7f49cf0074176ab1: [MCRB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm). - alpha:projection-evidence:document:cc7282df06bf1457e84fba49b1b5006e71fdb6006f0c9fb11fdaa85d5b5b8012: [MCRB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm). - alpha:projection-evidence:document:0048cf182e700feccd7187b3095004167edeb62ce4ff05a1c7b53c2054b75e07: [MCRB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm). - alpha:projection-evidence:document:bfa66d750f86e894aecbec32e93f9813b75dae88ea0a24fe8f70a1c566df5c2c: [MCRB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm). - alpha:projection-evidence:document:c6aff36a5b15a84ab617f6187cd3568cf7a89476653d6afb0d27e6bc321860f2: [MCRB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/seres-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/seres-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/seres-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/seres-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Structured intelligence is not currently available. Existing published profile evidence remains accessible. ## Critical-risk oversight Snapshot as of 2026-10-16T04:23:00.126346+00:00; recorded 2026-10-16T04:23:00.126346+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.